JOHNSON & JOHNSON SERVICES INC.

Products

Category

Product

Brand

Description

Gastrointestinal Therapeutics and Diagnostics (PHM046D)

Stelara (ustekinumab)		A bowel anti-inflammatory drug. It is a biologic treatment for numerous immune-mediated inflammatory diseases, including Crohn’s disease and ulcerative colitis. Stelara’s composition of matter U.S. patent expired in September 2023. The latest expiring European composition of matter patent expires in 2024.
Remicade (infliximab)		A bowel anti-inflammatory drug. A biologic treatment for numerous immune-mediated inflammatory diseases, including Crohn’s disease and ulcerative colitis.
Simponi (golimumab)		A bowel anti-inflammatory drug. A biologic treatment for numerous immune-mediated inflammatory diseases, including ulcerative colitis.

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment